NRX Pharma Inc. (NRXP) stock prices were down by 6.37% as of the market closing on August 16th, 2021. This brought the price per share down to USD$14.25 at the end of the trading day. Subsequent premarket fluctuations have seen the stock rally by 5.26%, bringing it up to USD$15.00.
NRXP Stock’s Regulatory Filing
A majority of the primary clinical activities reported during the second quarter of fiscal 2021 centered around analysis and regulatory filing. The company filed data from its phase 2b/3 clinical trial of intravenous ZYESAMI for Covid-19 Respiratory Failure. The quarter also saw NRXP stock support its NIH-sponsored ACTIV3b Critical Care study of ZYESAMI as compared to isolated use and in combination with Veklury. Furthermore, the company reported supporting its BARDA-sponsored I-SPY trial of inhaled ZEYSAMI, as well as the NRx-sponsored trial of inhaled ZYESAMI.
Ramping Up Production
In regard to manufacturing, NRXP stock focused on the development of its first shelf-stable formulation of ZYESAMI. This was announced early in the third quarter of 2021, along with involvement in scaling up aviptadil drug substance. The scaling is set to increase 100,000 doses per manufacturing batch to an anticipated 3 million doses per batch. This will be combined with a 90% reduction in the cost per gram of aviptadil drug substance.
NRXP Stock’s Network of Partners
The company has engaged in successful collaborative negotiations with the Israeli Institute for Biological Research. These negotiations have resulted in a long term partnership that was announced in Q3 of fiscal 2021. NRXP stock announced having entered into a collaborative agreement with TFF Pharma to develop a dry powder reconstitutable form of ZYESAMI. This form of the treatment has demonstrated initial room temperature stability. This technology has no shown promise for the development of a drug powder version of the BriLife vaccine.
Addressing the Global Pandemic
Nonclinical data has suggested the effectiveness of the treatment in neutralizing antibody response to Covid-19 and its variants, including the Delta variant. In conjunction with the rapidity with which the vaccine technology can be modified, new variants that may emerge are expected to be covered. NRXP stock also initiated business development interactions with MannKind Corp.. These interactions will see the company leverage the Technosphere platform for future inhaled use of ZYESAMI.
Future Outlook for NRXP Stock
NRXP stock reported a strong second quarter of fiscal 2021, with company management executing their strategy to continue their trajectory of success. Current and potential investors are hopeful that the company will be able to facilitate significant and sustained increases in shareholder value.
